Gabapentin
1Provenance card
the boundary, as counts
Sources
4228 with DOI
6 strong · 28 moderate · 8 weak
Compilations
12026-04-28T01:26:32.333Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
33last ruled 2026-06-04
1 awaiting a ruling
Issued documents
42026-10-19T20:32:05.410Z
notice · info card · emergency
Searches
200 with no results
queries and counts on the build
Claims checked
8867 supported
67 supported · 21 not
Correspondence
0received
consent field ships in Phase 4
Edges
283
derivations recorded for this entity
Complete over 42 sources, 1 compilation, and 33 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/gabapentin/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-10-02srcSuicidality Risk of Newer Antiseizure Medications: A Meta-analysis
- 2026-10-02srcGabapentin for chronic neuropathic pain in adults
- 2026-10-02srcMechanisms of the gabapentinoids and alpha2delta-1 calcium channel subunit in neuropathic pain
- 2026-10-02srcPopulation pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1
- 2026-10-02srcAre antiepileptic drugs used in the treatment of migraine associated with an increased risk of suicidality?
- 2026-10-02srcGabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α2δ-1 Subunit in Rats
- 2026-10-02srcClinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function
- 2026-10-02srcGabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system
- 2026-10-02srcStructural basis for CaVα2δ:gabapentin binding
- 2026-10-02srcGabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report
- 2026-10-02srcInterindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults
- 2026-10-02srcThe Effect of Gabapentin on Acute Postoperative Pain in Patients Undergoing Total Knee Arthroplasty: A Meta-Analysis
- 2026-10-02srcBiochemistry and physiology of voltage-gated calcium channel trafficking: a target for gabapentinoid drugs
- 2026-10-02srcRisk to heroin users of polydrug use of pregabalin or gabapentin
- 2026-10-02srcGabapentinoids and Neuropathic Pain: Evaluation of the Quality of Randomised Controlled Trials: An Umbrella Review
- 2026-10-02srcSuicide by gabapentin overdose
- 2026-10-02srcGabapentin: Abuse, Dependence, and Withdrawal
- 2026-10-02srcPharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients
- 2026-10-02srcAdjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes
- 2026-10-02srcGabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study
- 2026-10-02srcThe increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin.
- 2026-10-02srcUpregulation of Dorsal Root Ganglion α2δ Calcium Channel Subunit and Its Correlation with Allodynia in Spinal Nerve-Injured Rats
- 2026-10-02srcA comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin
- 2026-10-02srcGabapentin in Mixed Drug Fatalities: Does this Frequent Analyte Deserve More Attention?
- 2026-10-02srcOn the addictive power of gabapentinoids: a mini-review
- 2026-10-02srcPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
- 2026-10-02srcGabapentin for alcohol use disorder: A good option, or cause for concern?
- 2026-10-02srcGabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach
- 2026-10-02srcEnzyme induction and inhibition by new antiepileptic drugs: a review of human studies
- 2026-10-02srcGabapentin withdrawal syndrome
- 2026-10-02srcGabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones
- 2026-10-02srcAntiepileptic drugs in the treatment of anxiety disorders: role in therapy
- 2026-10-02srcAbuse of Gabapentin is Associated with Opioid Addiction
- 2026-10-02srcDisposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys
- 2026-10-02srcDevelopmental toxicity studies in mice, rats, and rabbits with the anticonvulsant gabapentin
- 2026-10-02srcThe novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel
- 2026-10-02srcIsolation of the [3H]gabapentin-binding protein/alpha2delta Ca2+ channel subunit from porcine brain
- 2026-10-02srcUK reclassification of gabapentin as Class C Schedule 3 controlled drug
- 2026-10-02srcGabapentin: history and synthesis (Satzinger and Hartenstein 1975)
- 2026-10-02srcGabapentin LD50 and toxicity in rodents - FDA label and preclinical data
- 2026-10-02srcA Comprehensive Analysis of Jurisdiction-Specific Laws Related to Scheduling or Required Prescription Drug Monitoring of Gabapentin in the United States, 2016-2024
- 2026-10-02srcGabapentin physical properties: crystal structure, melting point, solubility
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-07-03proposaldependence · taper
- 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-04-28revisionRevision 1
- 2026-04-28genGeneration — pipeline-v5 · with 2 morepipeline-v5
- 2026-04-28rungeneration run
The same entries, as forms: six forms.